Article

Biopharmaceutics 4.0, Advanced Pre-Clinical Development of mRNA-Encoded Monoclonal Antibodies to Immunosuppressed Murine Models

Andreas Ouranidis 1,2,* , Theodora Choli-Papadopoulou 3 , Eleni T. Papachristou 3 , Rigini Papi 3 and Nikolaos Kostomitsopoulos 4

1 Department of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 Department of Chemical Engineering, Polytechnic School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
3 Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; tcholi@chem.auth.gr (T.C.-P.); epapachristou@chem.auth.gr (E.T.P.); rigini@chem.auth.gr (R.P.)
4 Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece; nkostom@bioacademy.gr

* Correspondence: ouranidis@auth.gr or ouranidis@cheng.auth.gr

Abstract: Administration of mRNA against SARS-CoV-2 has demonstrated sufficient efficacy, tolerability and clinical potential to disrupt the vaccination field. A multiple-arm, cohort randomized, mixed blind, placebo-controlled study was designed to investigate the in vivo expression of mRNA antibodies to immunosuppressed murine models to conduct efficacy, safety and bioavailability evaluation. Enabling 4.0 tools we reduced animal sacrifice, while interventions were designed compliant to HARRP and SPIRIT engagement: (a) Randomization, blinding; (b) pharmaceutical grade formulation, monitoring; (c) biochemical and histological analysis; and (d) theoretic, statistical analysis. Risk assessment molded the study orientations, according to the ARRIVE guidelines. The primary target of this protocol is the validation of the research hypothesis that autologous translation of Trastuzumab by in vitro transcribed mRNA-encoded antibodies to immunosuppressed animal models, is non-inferior to classical treatments. The secondary target is the comparative pharmacokinetic assessment of the novel scheme, between immunodeficient and healthy subjects. Herein, the debut clinical protocol, investigating the pharmacokinetic/pharmacodynamic impact of mRNA vaccination to immunodeficient organisms. Our design, contributes novel methodology to guide the preclinical development of RNA antibody modalities by resolving efficacy, tolerability and dose regime adjustment for special populations that are incapable of humoral defense.

Keywords: mRNA encoded antibodies; SARS–CoV-2; COVID-19; Trastuzumab; mRNA-vaccines; pharmacokinetics; immunodeficient; NOD/SCID/J; biopharmaceutics 4.0; IVT mRNA

1. Introduction

Although equipped with a finite gene repertoire, the human immune system effectively encounters numerous pathogens and antigens over the lifespan cycle, by generating fit-to-purpose immunoglobulins [1]. B-immune cells endeavor this mission by executing a unique set of bioprocesses, i.e., splicing, gene segment recombination and random nucleotide insertion in order to form the B-cell receptors, which in turn, pass through elimination selection drill of self-reactive and nonproductive specificities [2], in order to produce the heavy and light immunoglobulin chains. The latter, self-assemble to deliver a mature, non-self-reactive antigen recognition molecular machinery, eventually transformed to the secreted antibody structure [3].

In particular, the IgG of the antibody isotypes is the one comprising the majority of serum immunoglobulins and features the greatest stability [4]. The human and mouse
IgG subclasses present morphological and functional similarities, both being suitable for neutralizing toxins and viruses [5]. Moreover, they demonstrate participation activity similarities towards secondary responses, whilst opsonization occurs when the variable antibody portion (Fab) binds to the cell membrane target, thus, forming the immune complex. Neutrophils and monocytes recognize the Fc antibody region using their activating receptors and induce T-cell responses promoted by the MHC antigen presentation responsible for the pathogen elimination [6]. Antibodies are recognized by the expressed NK cell Fc receptor, bound to pathogens, encompassing the antibody-dependent cell-mediated cytotoxicity (ADCC), releasing cytokines and effecting cellular apoptosis [7].

A monoclonal antibody (mAb) is an artificial, antigen-specific immunoglobulin, derived by the cloning of a unique parent white blood cell [8]. Monoclonal antibodies have been excessively used to treat cancers with proven safety. In particular, the recombinant, humanized, Trastuzumab (TZM) IgG1 class monoclonal antibody, binds selectively to the extracellular domain of the human epidermal factor receptor 2 (HER2), inhibiting the signaling pathways, reducing the mechanism of angiogenesis [9]. It was recently showed experimentally and with advanced numeric tools that the HER2–Trastuzumab interaction is much more heterogeneous than understood before, with two lumped pairs of kd and ka, respectively [10]. Marketed TZM is a sterile, pale yellow, lyophilized, preservative-free powder, reconstituted in bacteriostatic water solution prior to intravenous administration, authorized by the EMA and FDA regulatory bodies for the management and/or treatment of HER2 neu-positive breast (BC) and gastric (GC) cancer [11]. The recommended infusion weight-based dose regime emancipates 8 mg/kg loading followed by 6 mg/kg of maintenance protocols, administrated every three to four weeks [12]. Trastuzumab pharmacokinetics have been found to exhibit both linear and nonlinear elimination, the latter being attributed to mediated drug disposition [13]. At a steady state, a total clearance rate and a half-life terminal elimination period of 0.24 L/h and 30 days, have been respectively observed [14]. The large scale production of TZM features intrinsic complexities namely the aberrant post-translational modifications, tedious purification protocols, quality control hurdles, mammalian antibody-producing culture mutations and non-passage stabilization events [15]. Moreover, TZM mAbs appear oversensitive to clearance mechanisms and enzymic serum degradation, thus, requiring frequently repeated dosing, i.e., an intervention scheme that augments the risk of unwanted adverse effects such as immunologic activation [16], while also increasing the related health system expenditure. Alternatively, TZM antibodies may be designed as software source code under the enabling 4.0th industrial age computation tools [17], and are produced on demand by the preparation of in vitro transcribed (IVT) mRNA [18].

The latter, has demonstrated the potential to deliver translational therapeutic concentration levels of proteinc constructs and superiority of safety when compared to viral vectors and/or DNA plasmid transfection, due its transient nature [19]. Elaborating on this, the risk of insertional mutagenesis is insignificant with IVTs, hence the iterated mRNA code fragments never penetrate the cell nucleus [18]. In addition, IVT mRNA does not require the cumbersome handling of eukaryotic cultures, presents uniform quality, while the autologous translation pathway ameliorates the risk of any inappropriate post-translational modifications in a biomimetic fashion [20]. Expanding, the IVT mRNA allows for the natural glycosylation associated to the Fc immunoglobulin domain, which critically affects the antibody function. The N-linked site of glycosylation is located at Asn297 on both -CH₂ domains, forming a biantennary heptasaccharide consisting of mannose and N-acetylglucosamine [21]. Functional variations of terminal galactose, sialic acid, N-acetylgalactosamine and core fucosylation are located within the two glycosylation sites leading to 32 possible patterns. The glycans interact with the hydrophobic pocket of the Fc domain stabilizing the immunoglobulin [22]. Glycans influence the binding to the Fc receptors of immune mediators and effector cells. N-glycan at the conserved Asn297 locus has been pointed as critical for the binding of IgG with FcγR making significant contribution to in vivo functionality. Antibody-dependent cellular cytotoxicity (ADCC) mechanism of
coated antigens activates the monocytes to bind on the FcγR complex [23]. Moreover the complement dependent cytotoxicity (CDC), dependent of glycosylation events, requires the presence of a complex domain containing at least two N-acetylglycosamines and multiple sialic acids and galactoses [24].

The humoral, thymus-dependent immune responses are interlinked with the immunoglobulin-mediated antigen recognition and binding to Ig receptors of B-cells, fueling the consequent intracellular signaling transduction [25]. The decomposition signal of the C3 supplement initiates a second, meta-signal, activating the clonal expansion of the B-cells, inducing the somatic mutations of the immunoglobulin V domains of the gene repertoire. The iterated natural mechanism, is circumvented in the case of IVT-mRNA encoded antibodies, whereas the biosynthesis of the latter is attributed to the autologous ribosomal translation process [18]. This response follows the provision of the mRNA poly-peptidic decoding which in turn circumvents the natural immune pathway order. Immunosenescence is a state of inability of the immune system, prevalent to elderly patients, according to which B-cell responses, antibody titres and cytokine production become reduced. For such special patient populations, the administration of mRNA encoded antibodies might offer improved treatment efficacy.

Indeed, under this scientific hypothesis, apart from the lymphocytes, a wide variety of unchartered cell species may also function as alternative bioreactors of immunoglobulin synthesis. Contemplating the scenario that these in vivo produced immunoglobulins are structurally complete and functionally capable, our findings would aid the discovery of a novel pharmacokinetic and pharmacodynamic profile of antibody bioavailability for immunodeficient subjects. Given the wide application of the mRNA technology to several diseases, including anti COVID-19 vaccination [26], our experimental efforts would contribute usefully, both basic and applied, in research.

Therefore, the primary target of the presented pre-clinical trial protocol, is the experimental validation of the research scenario that the autologous decoding of antibodies via administration to immunosuppressed animal models, being incapable of producing their natural antibodies, is non-inferior when compared to classical TZM protein treatment. In line with this, the escorting measurements taking place include the quantification of biodistribution IVT-mRNA encoded antibodies and their carriers via histological microscopy. Furthermore, a basic metabolic, toxicological and inflammation panel of blood markers shall elucidate the corresponding adverse effects and the systemic biodistribution of the test drug substance. The secondary target refers to a PK comparative assessment of the novel drug treatment between immunodeficient strains versus healthy populations. The pilar pharmacokinetic measurements amongst others that will take place for both PK related arms are the area under the curve (AUC), maximum concentration (C_{max}), time T_{max} of accomplished C_{max}, half-life (t_{1/2}) and maximum observed response (E_{max}).

2. Materials and Methods
2.1. Recruitment and Animal Justification towards Future Extrapolation to Human Populations

NOD.CB17-Prkdc\textsuperscript{scid}\textsuperscript{J} (NOD/SCID/J) immunodeficient inbred [27,28] and C57BL/6 [29] mice will be purchased from Charles River (https://www.criver.com/products-services/find-model/jax-nod-scid-mice?region=3616, accessed on 2 August 2021), France and will be maintained in the animal facility of the Biomedical Research Foundation of the Academy of Athens under Specific Pathogen Free (SPF) conditions. Mice will enter to the experiments at the age of 10–21 weeks old. All mice will have ad libitum access to filtered tap water in drinking bottles and a pelleted chow that contained 18.5% protein, 5.5% fat, 4.5% finer, and 6%
ash (4RF22, Mucedola, Milan, Italy). The bedding in each cage of the three housing systems will be comprised of autoclaved corn cob bedding (240 g; Rehofix MK 2000, J. Rettenmaier and Sons, Rosenberg, Germany) while cage and bedding changes will be made once per week. Dirty cages of all groups will be changed under a cage change station (Interactive SafeChange™, Tecniplast, Buguggiate, Italy). The choice of NOD/SCID/J mice mirrors the pre-clinical trial’s directive to perform the experiments on a severely immunodeficient phenotype [30]. The latter, refers to a lack of both functional B- and T- lymphocytes, either due to the Prkdc (protein kinase DNA activated, catalytic polypeptide: DNA-PKCs) deletion or to the absence of variable (V)-diversity (D)-joining (J) (V(D)J) recombination [31]. The selected animal model carries multiple, precious for our study, abnormalities of the immune system, including the loss of impaired and complement NKs, dendritic cells and macrophage functions [32]. Moreover, NOD/SCID/J strain, in particular, are insulinis- and diabetes- free throughout life span and therefore none of exogenous inflammation incidents are prone to disrupt the credibility of the model [33]. Consequently, the NOD/SCID/J animal model is justified as our preferred animal type, to evidently serve as the study investigation model, hence, it fully meets the requirements of the in vivo mAb pharmacometric study of functional immunoglobulins being generated by non b-lymphocytic cell factories. In addition, the C57BL/6/J mouse ascends as the coupled model of choice, fulfilling the scope of the regression comparative analysis control, hence, exhibiting the nearest possible ancestral affinity to simulate the healthy physiological immune system. Only male murine models will be recruited in a single round draft reflecting our efforts to avoid any unwanted physiological sex dependent variance on the pharmacokinetic and biochemical corresponding variables investigated [34].

2.2. Study Design and Setting

A two-month, observational non-inferiority multiple-arm and stage cohort randomized, premier, double mixed blind placebo-controlled, single-centered trial was thoroughly designed to investigate the in vivo expression of mRNA encoded TZM monoclonal antibodies in immuno-suppressed animal models and drive extrapolating efficacy, safety and pharmacokinetic conclusions. The study falls to the sector of translational, precision oncology medicine of novel mRNA modalities and formulations, aiming to combat the human condition of breast and gastric HER2 positive cancer and extrapolate the pharmacokinetic and pharmacodynamic behavior, for the said special human populations. For this purpose, each animal of the engagement is considered as the experimental work unit of the study, taking into assessment a dropout rate of ≤ 10%. We proceed towards the enrollment of total 168 mice subjects in our accredited clinical cite, under the acceptance and monitoring of the relevant veterinary and bioethics committee. This study is designed in accordance with the latest of the veterinary and GCP guidelines for human medicine [35], namely the “International Cooperation on Harmonization of Technical Requirements for Registration of Human Products” and the “GL9 Good Clinical Practices” [36], the European Agency for the Evaluation of Medicinal Products (EMEA) “Guideline on statistical principles for veterinary clinical trials”, EMEA/CVMP/816/00-FINAL [37]. The study has been approved by the Institutional Project Evaluation Committee on the 26 February 2021 (Ref. Num. 148/26-02-2021), by the Directorate of Veterinary Department of Helenic Republic (272243/07-04-2021.300627) and strictly follows the (ARRIVE) ‘Animal Research: Reporting in-Vivo Experiments’ protocol guidelines’ [38] as they have been updated [39] for future human use.

The study is single centered, the work packages including the preparation of the drug doses as well as the clinical validation and analysis will be conducted by a control access SPF accredited facility, namely the Laboratory Animal Facility of the Biomedical Research Foundation of the Academy of Athens (BRFAA). This model study, as demonstrated by Figure 1, utilizes enabling modelling tools of the 4.0 industrial age to reduce animal sacrifice, while research actions are performed at multiple levels of engagement to ensure extrapolating results for future human trial protocols: (a) Randomization, blinding, decoding (b) drug formulation, administrations conduct and monitoring; (c) outcome mea-
measurements, i.e., biological, histological and chemical analysis documentation; (d) theoretical explanation of results; and (e) statistical analysis and final reporting.

Figure 1. Schematic overview of the preparation and clinical validation of TZM antibodies encoded by mRNA.

2.3. Experimental Protocol, Animal Handling and Data Collection

All murine models are housed in accordance to the European Directive 2010/63 and the “Guide for the Care and Use of Laboratory Animals” [40]. A Building Managing System (BMS), monitors the electromechanical equipment of the facility, 24 h per day and documents hazardous alterations. The murine models recruited belong to either A or B cohort, namely the C57BL/6/J and NOD/SCID/J type respectively and are further taxonomized into the following intervention groups in order to fulfill the clinical study design: (a) A1, B1 of negative control that consists of 2 mice per type that will receive \( n = 4 \) parenteral concentrate natural saline solution, (b) A2, B2 of placebo control that consists of 2 mice per type \( n = 4 \), placebo being a substance of identical visual characteristics, (c) A3, B3 that consists of 36 mice per type \( n = 72 \) receiving the carrier and IVT-mRNA encoding for the active pharmaceutical ingredient TZM, (d) A4, B4 positive control that consists of 36 mice per type \( n = 72 \) receiving the API TZM with the commercial carrier Herceptin, (e) A5, B5 that consists of 4 mice per type \( n = 8 \) receiving mRNA GFP to guide the comparative tissue study, (f) A6, B6 that consists of 4 mice per type \( n = 8 \) receiving protein GFP as positive control.

The day of the experimental administrations, all murine models shall have access to water and remain on fasted state for at least 8 h before infusion. The total infusion dose of the mRNA modality or control or signal indicative protein will for all groups be in concentrations that correlate to the established antibody, weight-based dose regime of 2 mg/kg. The total volumetric dose of the protein and carrier will be set at 100 µL in concentrations that are in line with the established antibody weight-based dose regime of 8 mg/kg. Pericardiocentesis of the animal subjects will be implemented towards the collection of blood samples (0.5–0.7 mL) for the time intervals of \( t = 12 \) days for the groups A1 and B1, \( t = 12, 24 \) days for the groups A2 and B2, \( t = 0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 12, 24, 28 \) days for the groups A3, B3, A4 and B4. The groups A5, B5 and A6, B6 will receive histopathological examination at the time points \( t = 6, 18, 24, 28 \) days in order to quantify the biodistribution of the mRNA to the several tissues after intravenous administration. The designed intervention groups under the HARRP guideline are presented by Table 1.

The blood samples obtained will be kept in appropriate, sterile tubing and centrifuged in 4 °C for 5 min at 2000 × g, plasma will be separated and collected and the supernatant will be isolated and documented for each working group and finally stored in deep freezer (−80 °C), conserved for the quantification analysis steps by ELISA and followed by LC-MS validation. The overview of the pre-clinical design is presented by the poster of Figure 2.

In order to achieve the outmost of the experimental resources and ensure robustness and seamless pre-clinical implementation, reduce future protocol amendments and advance towards the facilitation of the study’s both ethical and scientific considerations appraisal, the SPIRIT statement has been archived to inform all the stages of the trial [41]. In Table S2 of the Supplementary Materials the Schedule of enrolment, allocation, interventions and control assessments, aligned to the SPIRIT guidelines are presented.
Table 1. Intervention schedule for each animal type according to dose regime and substance administrated for the time monitoring checkpoints.

| Group | Type            | Intervention                  | Route | Mice (n) | W.B.D. Regime (mg/Kg) | Dose (µL) | Monitoring Intervals (Days) |
|-------|-----------------|-------------------------------|-------|----------|-----------------------|-----------|----------------------------|
| A1    | C57BL/6/J       | Saline Solution               | Iv    | 2        | -                     | 100       | 12                         |
| B1    | NOD/SCID/J      | Saline Solution               | Iv    | 2        | -                     | 100       | 12                         |
| A2    | C57BL/6/J       | Placebo                       | Iv    | 2        | -                     | 100       | 12, 24                     |
| B2    | NOD/SCID/J      | Placebo                       | Iv    | 2        | -                     | 100       | 12, 24                     |
| A3    | C57BL/6/J       | Trastuzumab (mRNA + Carrier) | Iv    | 36       | 2                     | 40        | 0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 12, 24, 28 |
| B3    | NOD/SCID/J      | Trastuzumab (mRNA + Carrier) | Iv    | 36       | 2                     | 40        | 0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 12, 24, 28 |
| A4    | C57BL/6/J       | Trastuzumab (Protein)         | Iv    | 36       | 8                     | 160       | 0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 12, 24, 28 |
| B4    | NOD/SCID/J      | Trastuzumab (Protein)         | Iv    | 36       | 8                     | 160       | 0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 12, 24, 28 |
| A5    | C57BL/6/J       | mRNA GFP                      | Iv    | 4        | 2                     | 40        | 6, 18, 24, 28              |
| B5    | NOD/SCID/J      | mRNA GFP                      | Iv    | 4        | 2                     | 40        | 6, 18, 24, 28              |
| A6    | C57BL/6/J       | GFP (Protein)                 | Iv    | 4        | 8                     | 160       | 6, 18, 24, 28              |
| B6    | NOD/SCID/J      | GFP (Protein)                 | Iv    | 4        | 8                     | 160       | 6, 18, 24, 28              |

Figure 2. Overview of the pre-clinical trial design points.
2.4. Randomization and Blinding

Each mouse subject will be assigned a randomized block before launching the work packages of the protocol. Given the restricted sample size of our preclinical study, a stratified randomization technique has been extended to include the “Guidelines and Initiatives for Good Research Practice” [42] for all working animal groups, being identified before group assignment. This method implements principles of probability theory [43] in order to assess the likelihood as a source of difference between the delivered outcomes, thus enabling the application of central limit theorem [44] based tests, evaluating the minimum statistically viable animal sample number, utilizing the developmental algorithm found at (https://www.randomizer.org/, accessed on 8 February 2021). Following the proposed arrangement scheme the sample characteristics are maintained homogenous and consistently representative of the typical population. Moreover, the sample may be drawn by any experimental group at any given time point, hence all the animal units receive monodose administrations via intravenous route and with equal pre-treatment handling. Each treatment group will be matched with a separate color mark indicated on its tail. The identical simple to discern coding, will be applied for: (a) Vials containing the experimental drug; (b) controls and placebo; and (c) syringes used to infuse the tested substances.

Following the iterated discrimination and in an effort to achieve satisfaction of the relevant GCP compliant directives, data integrity will be monitored in real time within the active clinical period. Due to the fact that the protocol will be executed stepwise and that the subjects will, at all times, be handled by a limited member team of experienced scientists, a partial blinding during the experimental treatment will suffice and will be followed by a full blinding only during the phases of data collection and analysis [42]. This decision is justified by the fact that the under-investigation drug suspensions are of similar physicochemical feature and appearance, identical viscosity, thus, constituting visual recognition an impossible task.

In relation to such infusions, researchers have questioned the robustness of masking of content ingredients as blinding method, hence, visual inspection is acknowledged as a safety precaution standard, and thus, advocates that the acceptability of this technique should be limited. Therefore, in certain cases similar to our protocol, the deployment of unblinded or partially unblinded handling using color coding, though not perfect, does not lead necessarily to unblinded conditions. Indeed the limiting of the personnel access to that of analyzing treatment results only, offers counter measures balancing against inappropriate unblinding [45].

2.5. Statistical Methods and Preliminary Feasibility Report

To assess the minimum sample of murine models required to produce meaningful statistical results, a non-inferiority t-test for two independent means power analysis was conducted by the software nQuery Cork, Ireland, covering the pilar pharmacokinetic experimental groups: (a) The A3 and B3 groups; and (b) A4 and B4 groups, respectively. We have predefined the delta \( \Delta_o \) margin of noninferiority hypothesis limit difference to be 20 \( \text{ug/mL} \) plasma concentration in order to define the therapeutic interchangeability [46].

The results showed that for sample size in both groups being three, a one-sided two group \( 0.05 \) significance level \( t \)-test has 80.49% power of rejecting the null hypothesis that the standard and test are not non-inferior (the difference in means being 20 or farther from zero in the same direction), in favor of the alternative hypothesis that the means of the two groups are non-inferior. This assumes that the expected difference in means is 0.001 and the common standard deviation is 8.

Moreover, based on the existing experimental data and results published by relevant mAb clinical trials in human and animal subjects [47], we attempted to chart a prediction of the expected PK profile of antibody expression, post the intravenous infusion of lipid nanoparticles containing TZM encoded by the mRNA constructs, regarding the A5, B5 and A6, B6 groups. The scenario advocates the restricted measurement of therapeutic antibody
concentration for the experimental unit, allowing for almost two-fold reduction of the animal subjects’ number and is presented by Figure 3a.

![Figure 3. Concentration curves of TZM over time after intra venous infusion: (a) Predicted critical time window of interest based on projections of bibliographic data; (b) IWRES versus IPRED for predicted data of mAb infusion as full-length protein.](image)

Elaborating on the former statement, by performing the above preliminary analysis, we were able to restrict the observation of our experimental work plan within the time frame of 60 days and further define the window of dense sampling to focus the chronic period between days 0 and 28, as indicated by the ellipse of Figure 3a. The individual weighted residuals IWRES plotted against individual predicted values (IPRED, predicted concentrations) for the antibody pharmacokinetic profile is demonstrated by Figure 3b, showing that the observed against fitted values fall close to the line of unity, thus, demonstrating the feasibility of our approach.

Due to the modular nature of our design we hereby are able to introduce a parallel, custom statistical observation method presented by Table 2, whereby, subjects are initially taxonomized for each animal type and are stratified according to the weight-based dosing regimen administration for each time interval, delivering a response contour space suitable for scanning the desired levels of TZM systemic bioavailability.

Table 2. Stratification of the animal model and dosing levels W.B.D. over time to search the design space for the optimum bioavailability.

| Factor | Name            | Units  | Type         | Minimum | Maximum | Levels |
|--------|-----------------|--------|--------------|---------|---------|--------|
| A      | Animal Model    | Categoric | C57BL/6/J   | NOD/SCID/J | Levels: | 2      |
| B      | Dosing W.B.D.   | mg/Kg  | Categoric    | 2       | 8       | Levels: | 2      |
| C      | Time            | days   | Categoric    | 0.5     | 28      | Levels: | 12     |

The above design is implemented to aid the comprehensiveness of the statistical output translation, hence multiple interventions are studied simultaneously decreasing the participant subject’s number. This design is schematically represented by Figure 4, showing the dual factorial levels being employed for animal model type, namely C57BL/6/J and NOD/SCID/J, binary levels for W.B.D. dosing namely 2 mg/kg and 8 mg/kg and 12 levels for time checkpoints (0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 12, 24, 28) days and with the final response being appointed to the TZM accumulation in blood post-infusion measured in concentration units of mg/mL.

2.6. Preparation of Drug API Lead mRNA and Vehicle Formulation

The lead of mRNA constructs have been hierarchically designed by rational bioinformatic abstraction methods as autonomous functional genetic circuits, i.e., masking physical
The codon sequences were aligned to the PDB humanized TZM antibody and the BLOSUM62 algorithm was used to define the percentage of differentiation [51]. Compared to the wild type of TZM several technical mutations have been appointed: (a) G (guanine)/C (cytosine) enrichment of the coding sequence (CDS) locus capable of producing stable rich A (adenine)/U (uracil) transcripts based on codon degeneration [52], (b) codon-recognized tRNAs insertions [53], (c) replacement of AURES of 3′ UTR sequences recognized by Toll like receptors and nucleases [54], (d) post-transcriptional capping anti-reverse analog (ARCA), modified nucleotides (5-Methylcytidine-5′-Triphosphate and Pseudouridine-5′-Triphosphate) to enhance the stability and reduce the immune response of host mammalian cells, (d) 3′-PolyA-tail addition to increase translation efficiency of transfected cells by the recruitment of poly(A) binding proteins, conferring also stability by inhibiting exonuclease activity, (e) Kozak sequence (GCCGCCACCAUGG) binding to ribosome translational enhancer, (f) IRES (Internal Ribosome Site) polycistronic mRNA transcriptomic enhancer, (g) UTR stabilizing sequences 5′ of b globulin, (h) secretory signal.

In detail, we performed the proof of concept protocol, utilizing T7 RNA polymerase to evaluate the in vitro transcription and potency of mRNA expression of TZM for the transfection of mammalian cell cultures. The latter was used to transcribe the designed linearized DNA template into mRNA, (HiScribe T7 ARCA mRNA Synthesis Kit, NEB Biolabs). Subsequently, the reaction was incubated at 37 °C for 30 min and treated with DNase to remove excess template DNA [55].

The CDS light V_L and heavy V_H chains were optimized and integrated to the pVITRO1 plasmid backbone (see Figure 5a), based on the latest of leges artis methodology, in an effort to improve stability and translationability of the investigated mRNA modalities. In Figure 5a,b, the plasmid construction and the induced mutations that lead to stability and functionality of our mRNA lead, are revealed. In addition, purification of RNAs from enzymatic synthesis or modification reactions, an essential process prior to mammalian cell transfection, was performed. Expanding on the former statement, upon mRNA synthesis by in vitro transcription, unincorporated nucleotides, short aborted transcripts, small molecule, enzyme reaction and buffer components were removed before formulating the mRNA. For the purification of mRNA, we used the Monarch RNA Cleanup Kit (NEB Biolabs). The Monarch RNA Cleanup Kits provide a fast and simple column-based solution for RNA cleanup and concentration (binding capacities: 10 µg, 50 µg) after in vitro transcription [56].
The synthesized mRNA within the lipid carrier (mRNA/jetMESSENGER® ratio 1:2), was eventually used for the transient transfection of Chinese hamster ovary CHO-K1 (Registered Code: CCL-61, Sourced by: ATCC) wild type; American Type Culture Collection, Rockville, MD, USA) cells while the optimal culture conditions were determined for the biosynthesis of TZM. After 48 h of incubation, transfected CHO-K1 cells were selected out, the cytoplasmic RNA was isolated and assessed by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) analysis, for the steady-state level assessment of TZM RNA transcripts that were encoded by the Heavy and Light Chains, respectively. After 72 h, the culture supernatant of transfected CHO-K1 cells was collected, containing the TZM antibody. MCF7 (Registered Code : HTB-22, Sourced by: ATCCcell line) positive HER2+ receptor were incubated with the supernatant of the transfected CHO-K1 colony with DMEM 10% FBS at 37 °C and 5% CO2 for 72 h and the evaluation of cell viability was detected by the live/dead fluorescence staining. Cells were finally double stained with Calcein AM and Ethidium Homodimer-EthD1 (live/dead respectively) and were visualized under a confocal microscope (Leica Microsystems, Wetzlar, Germany), as shown by Figure 6a,b.

Conclusively having demonstrated proof of concept, several lipid vehicle nanoparticles (LNPs) shall be prepared towards the pre-clinical trial implementation, containing mixtures of DSPC: Chol: DOTAP: DMGPEG 2000 by individual lipid stocks kept in ethanol. Lipid mixture will be dissolved at 2 mg/mL in ethanol at several quality by design pre-defined molar ratios [57]. Citrate buffer of pH 6 at 100 mM will be exploited to serve for
the aqueous dispersion phase. The effect of several coatings (DMG-PEG2000 vs. DSPE-PEG2000), condensing polymeric agents (DDAB, DOTAP or MC3) and structural lipids (HSPC vs. DSPC) will be assessed [58]. For the preparation of the encapsulating mRNA, an aqueous phase of citrate buffer regulated at pH 6, 100 mM and presenting a nitrogen (from the cationic lipid) over phosphate (from the nucleic acid) ratio of 8, shall be prepared [59]. Formulations will be subjected to dialysis for the period of 1 h under magnetic stirring conditions, in 200 mL TRIS buffer maintenance in order to avoid sensitivities against high-salt containing buffers and reduce the solvent residues below the regulatory target of 5000 ppm [59].

2.7. Risk Assessment

A risk assessment complementary study has been conducted to ensure the credibility of the results by projecting eminent hazards, advice an early action plan and avoid the unethical loss of animals in strict accordance to the ARRIVE guidelines [39], as demonstrated by Figure 7. Combined immune deficiency, spontaneous mutant mice do not acquire functional T-cells and B-cells, while myeloid, antigen-presenting and NK cell functions depend on the selected strain. These homozygotes do not possess Ig-G1, G2a, G2b, G3, A, M, in detectable quantities in their lymph nodes, thymus and splenic follicles, being devoid of any lymphocytic type [30]. Although a limited portion of SCID mice may develop weak immune reactivity spontaneously, leakiness is found in alarming levels in subjects that are housed in facilities that do not support proper SPF conditions.

Figure 7. Fish bone diagram of risk assessment demonstrating the factors that critically alternate the validity of the obtained results and effect reproducibility and extrapolation, spanning the sectors of animal type, experimental unit preference, mRNA, analysis methods, carrier and statistical methods employed.

Moreover, thymic lymphomas do occur at extremely high frequencies, while the expected life span is limited for these animals to only 8.5 months under pathogen-free conditions [27]. There exist numerous variables that may irrevocably compromise the primary target of our clinical study and constitute the latter a demanding one, namely the: (a) Iterated frail idiosyncrasy of the need based chosen animal model, enhanced by the SPF environment of the clinical setting; (b) intravenous administration in parallel, i.e., simultaneous fashion for all animal groups exposed; (c) medicine development study directives required by the regulatory authorities in compliance to the specific pharmacokinetic rules applied for medicines intended for future use in human; (d) accurate evaluation of the inflammation profile caused by the mRNA or the carrier or their combination after infusion.
to the bloodstream by biochemical characterization; (e) culture-mediated production and special storage conditions for the mRNA modalities when mixed with the carrier; (f) demand that results obtained must for all participating animal groups be reproducible and extrapolatable for human special populations.

Therefore, in order to avoid unacceptable quality failures and mitigate the above-mentioned risks, a cautionary plan regarding the appropriateness of the experimental drug and vehicle formulation, has been apriori integrated to our design. Under this lens, all necessary trial materials in contact with the murine models will be handled aseptically and all relevant substance preparations will be conducted strictly in laminar flow conditions conforming to GMP regulation, taking advantage of the inhouse GLP accredited facility located in the same complex with the clinical setting [60]. All starting material of the carrier and mRNA shall meet the requirements of either pharmaceutical quality grade or at least suitable for veterinary use approaching the analogous biological and chemical purity specification limits posed by the European Pharmacopoeia ruling [61]. A qualified person appointed by the study sponsor and preferably specialized in GMP manufacturing will audit and register the data twice in separate locations and verify that conditions are met before unleashing the clinical batch [62].

2.8. Histological Examination and Toxicity Studies

Evaluation of alterations caused by novel drugs to the experimental units of a clinical investigation represents the pilar of any safety assessment before applied to human patients. The latter is based on conventional histopathological tests, representing a significant contribution to novel treatment development for both human and animal diseases [63]. We will evaluate malignant alterations to all organs and their corresponding tissues and investigate the causal relationship that might have been developed due to the novel drug treatment exposure and also assess the relevance that the various adverse effect related findings might have for future patients [64]. For the groups A5, B5 and A6, B6 detailed drug biodistribution and toxicity analysis will be conducted followed by the histological examination utilizing fluorescent optical microscopy techniques (DAPI, GFP) exploiting the Bitplane Imaris, ImageJ software to assess signal quantification [65]. For the rest of the groups blood escorting biochemical and hematological tests will be conducted to include the biomarker metrics [66] that are revealed in detail by Table 3.

Table 3. Toxicity and inflammation effects of interventions to be measured by the various parameters of serum.

| Parameters of Serum | Effects of Interventions to be Measured |
|---------------------|----------------------------------------|
| Leukocytes          | BA, MO, LY, NE, WBC                    |
| Erythrocytes        | RDW, MCHC, MCH, MCV                    |
| Thrombocytes        | PLT, Anion Gap, Potassium, Bicarbonate |
| Miscellaneous       | Phosphorus, Sodium, Alk Phos, AST      |
|                     | Globulin, Cholesterol, Bilirubin       |
|                     | CK Bilirubin Conjugated, Creatinine    |
|                     | BUN/Creatinine, Chloride, Glucose     |
| Total Bilirubin     | Total Protein, Albumin, NA/K           |
| Unconjugated        |                                       |

2.9. Data Collection Analysis and Pharmacokinetic Simulations

Compared to small organic APIs, mAbs are characterized by limited transcapillary and tissue permeability, enhanced hepatic metabolism and renal filtration in combination with Brambell receptors salvage, peripheral clearance and nonlinear mass transport caused by receptor binding [67]. The pharmacokinetic study variables and formal data analysis method is summoned by Table 4.
Table 4. Study parameters and relevant data will be collected and monitored by the investigator team assessing the PK/PD effects. The following table provides an overview of the planned PK variables and their corresponding calculation methods.

| Measuring Points | E.1, KM.1 | E.2, KM.1 | PK.1, KM.2 | PK.2, KM.2, KM.3 |
|------------------|-----------|-----------|------------|------------------|
| Study Day        | D 0–12    | D 24      | D 28       | D 60             |

| Study variable   | Variable type | Outc. | Covar. | Variable Description | Unit |
|------------------|---------------|-------|--------|----------------------|------|
| Demographics     |               |       |        |                      |      |
| Body weight      | X             |       |        | Subjects mass        | gr   |
| Age              | X             |       |        | Age classification   | months |
| Temperature      | X             |       |        | Body temperature measurements | °C |
| Dose (D)         |               |       |        | Amount of drug to be administered | mg/kg |
| AUC              | X             |       |        | Total area under the plasma drug concentration | (µg × h/mL) |
| AUMC             | X             |       |        | Total area under the first moment curve | (µg × h²/mL) |
| Drug conc.       |               |       |        |                      |      |
| A, B             | X             |       |        | Coefficients of biexponential equation | - |
| C_p(0)           | X             |       |        | Initial drug concentration in plasma | mL/h |
| C_p(12 h)        | X             |       |        | Plasma drug concentration at 12 h | mL/h |
| C_p(last)        | X             |       |        | Last measured plasma drug concentration | mL/h |
| C_p_(steady)    | X             |       |        | Plasma drug concentration at steady-state | mL/h |
| C_p(max)         | X             |       |        | Maximum desirable plasma drug concentration | mL/h |
| C_p(min)         | X             |       |        | Minimum effective plasma drug concentration | mL/h |
| C_p,ss(max)      | X             |       |        | Average plasma concentration | mL/h |
| C_p,ss(min)      | X             |       |        | Peak concentration of drug in blood plasma | mL/h |
| C_p,ss           | X             |       |        | Minimum concentration of drug in blood plasma | mL/h |
| Rate constants   |               |       |        |                      |      |
| a, b             | X             |       |        | Exponents of biexponential equation | - |
| k_12, k_21       | X             |       |        | First-order rate constants | - |
| k_a              | X             |       |        | First-order rate constant for elimination | - |
| k_d              | X             |       |        | Apparent first-order absorption rate constant | - |
| Time notations   |               |       |        |                      |      |
| t_1/2            | X             |       |        | Half-life | h |
| t_1/2(a)         | X             |       |        | Absorption half-life | h |
| t_1/2(d)         | X             |       |        | Apparent half-life | h |
| MRT              | X             |       |        | Mean residence time | h |
| MAT              | X             |       |        | Mean absorption time | h |
| t_max            | X             |       |        | Time at which peak plasma concentration occurs | h |
| Volume terms     |               |       |        |                      |      |
| V_d              | X             |       |        | Apparent volume of distribution based on AUC | L/kg |
| V_d(ste)         | X             |       |        | Apparent volume of distribution at steady-state | L/kg |
| V_e              | X             |       |        | Apparent volume of pharmacokinetic model | L/kg |
| Clearance        |               |       |        |                      |      |
| C_b              | X             |       |        | Body (systemic) clearance | mL/h kg |
| C_R             | X             |       |        | Renal clearance | mL/h kg |
| C_H             | X             |       |        | Hepatic clearance | mL/h kg |
| Q_organ          | X             |       |        | Clearance expressed on unit body weight basis | mL/h kg |

Both mAb diffusion through the lipid bilayers and distribution in the tissue interstitial space depend on convection through the pores of the endothelial vasculature and transcytosis. While, endosomal escape plays a critical role by ensuring the ribosomal translation event and the consequent transport to the interstitial space, thus, ameliorating the lysosome degradation processing. Modeling predictions will concern the evaluation of extravascular distribution, i.e., the transcapillary escape rate (TER) and protein localization [68]. A third-generation system-average physiologically based pharmacokinetic (PBPK) model has been considered for the relevant tissue types taking into account the mAb expression prodrug particularities. Moreover, the recent use of high-resolution biosensor technology, combined with advanced numeric tools, has revealed that all interactions, such as those based on monoclonal antibodies are more heterogenously than what has been previously understood. These effects are in fact embedded in the apparent PK/PD parameters presented by Table 4 [69]. The model interrogates the translation, convective transport uptake of IgG, endocytosis and organ distribution into three main compartments, i.e., vascular, endosomal, interstitial [70], and is demonstrated by the scheme of the Figure 8.

Targeted-mediated drug disposition (TMDD) and Toll like receptor inactivation will be integrated to the PBPK model coefficients in an effort to estimate the effects of receptor binding in the plasma and the interstitial space and the parameters describing the behavior of endogenous IgG will be experimentally fixed. The model will offer predictions for the mAb concentration against time for the investigated compartment types leaky and tight, and their clearance mechanisms assuming one-pore formalism, convection being the dominant distribution pathway and ISF as the main extravascular distribution space [68].
The algebraic model structure is principally described according to the relevant methods for Pharmacokinetic and Pharmacodynamic Data Analysis as described by J. Gabrielsson and D. Weiner [71] and is schematically appointed by the diagram of Figure 8.

**Figure 8.** Model structure of the PBPK TZM mRNA IVT for the plasma baseline concentrations. Whereas \( C_{RC,P} \) is the mAb mRNA TZM concentration found in plasma volume \( V_P \), \( C_d \) and \( C_{lq} \) are the mAb concentrations in ISF in the tissues dense and leaky of volumes \( V_d \) and \( V_{lq} \) and of continuous, and fenestrated capillaries, respectively. \( V_l \) is the lymph volume and assumed almost equal to blood volume. The \( F_L \) is the total lymph flow which is considered equal to the sum of \( F_{L,1} \) and \( F_{L,2} \) being the lymph flux for \( V_d \) and \( V_{lq} \) respectively. The \( \sigma_d \) and \( \sigma_l \) and the \( \sigma_d^* \) and \( \sigma_l^* \) being the coefficients of vascular reflection \( V_d \) and \( V_{lq} \) for the mRNA formulation and the correspondent TZM IgG, respectively. The \( CL_P \), \( CL_{in,1} \), \( CL_{in,1}^* \) and \( CL_{in,2} \), \( CL_{in,2}^* \) are the clearances for the plasma and ISF dense, leaky tissues for the mRNA formulation and the correspondent TZM IgG, respectively. Simulations of the predicted active tissue concentrations will be compared to the experimental measurements in order to evaluate the model performance. The areas under the concentration versus time curves (AUC0-t) will be calculated using the NCA bundle of Phoenix 8.1 (2021, Pharsight Corporation, Mountain View, CA) and predictions will be extrapolated using the same software for the relevant human populations.

2.10. **Statistical Analysis**

Upon study completion, collection and curation of data, statistical analysis will be implemented using SPSS (IBM Deutschland GmbH, Ehningen, Germany) and Prism GraphPad Software (San Diego, CA, USA).The results shall be considered as significant for \( p \) values < 0.05 and for the baseline and all efficacy and safety variables the following steps will be undertaken: (a) Individual concentration values will be documented and graphically presented for each experimental unit of each group; (b) descriptive statistics shall be tabulated for each experimental group per time intervals while the mean and standard error will be calculated and plotted; (c) for the discrete values a table of frequencies will be presented over time scale for each group; and (d) comparisons between the intervention treatments and placebos will utilize Student’s \( t \)-tests, Wilcoxon test ranks for non-parametric data while correlation interactions will be analyzed by Pearson’s coefficient calculation, and Spearman’s test, respectively. A combination of multivariate analysis will be adapted whether appropriate and a mixed effect models shall be considered.

3. **Discussion**

Implementing a multi arm, cohort randomized, premier, double blind placebo-controlled trial design should generate credible data to investigate the safety and non-inferiority of mRNA-encoded TZM antibodies, compared to the marketed substance, in order to aid the
development of a first line medication for immunodeficient patients suffering from HER2-neu breast and gastric cancer. If clinical endpoints are successfully reached and deliver significantly credible statistical results, our experimental efforts would establish the potential to investigate an alternative therapy for special populations, thus, covering an unmet need. This study will utilize a double and partially blinded, placebo-controlled protocol following a parallel design nomenclature. Considering that the designed features encumber the highest of quality preclinical standards, the challenges against the bibliographically known or expected biasing effects have been addressed. Animal participation and sacrifice has been minimized by the utilization of the latest fourth industrial age toolbox, borrowing traits and methods from current relevant human trial design paradigms. The block randomization, the initiation of placebo control, the two-level blinding features are evidently expected to ameliorate both the regression to the mean variance and the anticipated observer artifacts frequently occurring in mice studies [72], especially found when exploring precision medicine intended for future human use.

Such design significantly increases the representativeness and accuracy of results on the application of IVT-mRNA as alternative or first line therapy instead of monoclonal antibodies. Regression to the mean is critical for clinical investigations when variables range to extreme propensities, and when the selected population is either not uniform and/or the induced disease models are applied in uni-linear fashion [73]. In this preclinical study, we leverage on the recruitment of an established, reliable strain of a verified animal model that is borne with the artificial preferred phenotype and housed in clean, continuously monitored conditions [30]. The former in combination with the aseptic starting material and drug preparation, good clinical practice appropriate warehousing and handling advocate the opportunity to produce credible, repeatable results for any chromic interval, randomly chosen for validation [36].

The placebo effect has been established as of outmost importance element in human trial design but in pre-clinical practice it has been honored with limited application so far, especially when the immunology field and particularly for the involvement of mice models [74]. For the proposed implementation partum pendo, each experimental unit serves as if being the same organism, receiving treatment or control and being biochemically and physiologically tested at several points in time. In other words, this pre-clinical study presents an unusual “between patient”, “non-crossover” protocol of antibody testing, according to which distinct arms of treatment are administrated, such as the first group receives treatment arm A as pro drug and the alternate group receives treatment arm B drug as comparator [75]. Our two-parallel intervention treatments are composed of completely different formulations, doses, API chemistries and mechanism of action of the same principal drug substance. The advantage of this parallel design is the combined safety and non-inferiority assessment of the experimental drug as the critical endpoint of evaluation.

Furthermore, we incorporated the available internal validity criteria preached by the “Guidelines and Initiatives for Good Research Practice” [36], addressing the issues of randomization blinding. Both randomization and blinding interact with additional confounding variables in order to achieve reduction of bias risk [72]. Under this lens and taking into account our sample size we employed a tailored pseudo-randomization protocol based on a simple algorithm that can be applied repeatably by the personnel, thus ensuring that: (a) Experimental unit assignment is equal for each of the subjects; and (b) each assignment to any of the groups cannot affect the inclusion of any other subject to the same group. The subjects were allocated to either treatment or placebo conditions, maintaining the randomization state throughout the study conduct to avoid primary and secondary outcome performance bias.

Risk assessment analysis was applied, in order to decide the fit-for-purpose blinding type of for the specific study conditions, according to the ICH harmonization Principles of “Evidence-Based Medicine to Optimize Research Practices” ruling [76]. Blinding was justified as tailored by the needs of the specific experiment and balanced against the
existing standard operating procedures and the potential risks. For our clinical trial during the experimental treatment and the collection of biological samples, discrete color coding allows the efficient recording, so as full blinding will be implemented only when deemed necessary, i.e., during the analysis and interpretation steps [45]. Reliable results will be received following this pathway and avoiding the imminent complexity drawbacks of over blinding measures whereas our personnel will be required to handle vials that are beforehand presented as identical container units to any observer. Our non-inferiority trial incorporates a placebo and comparator, thus, we are pursuing multiple goals. We seek to establish superiority to placebo, validate the experimental design and at the same time evaluate the similarity of safety and efficacy to the comparator. Therefore, this trial cannot be classified as a typical equivalence venture hence it is not mission-conservative.

Unchartered complexities and design flaws or conduct misfits will certainly bias the results. Consequently, special care has been given to acknowledging, registering and where possible minimizing the associated risks and related violations of inclusion criteria, withdrawals, non-compliance, missing data, protocol and subsequent analysis deviations. The above are linked to several limitations of our study that may reflect negatively on the proper translation and extrapolation of data, such as the intention to treat analysis (ITTIA) may be challenging or impossible to perform [77]. Given the experimental unit is assumed as the singular investigated organism, where randomization is not successfully implemented, false AUC values may be incorporated to the statistical analysis describing an artifact PK, thus, leading to misfit of the extrapolation strategy. Moreover, the need for aseptic starting material and aseptic handling during the preparation and administration stage respectively, increase the trial implementation difficulty level, approaching in certain aspects those of human experimentation.

4. Conclusions

We performed non-inferiority pharmacokinetic studies to evaluate the safety and the curve of dose response exposure, prior to a detailed pharmacodynamics and efficacy assessment for IVT encoded TZM mAbs. Plasma and tissues will be collected and examined biochemically and histopathologically over the selected time milestones, in order to interpret the AUC results obtained. Further theoretical assessment of raw data will be approximated by PBPK modelling in an effort to explain and extrapolate the results for human special populations in need. To our knowledge, this is the first clinical trial designed to provide in-depth, the comparative pharmacokinetic and pharmacodynamic impact of mRNA-encoded monoclonal antibody vaccinations on immunodeficient organisms and meaningful data regarding safety and efficacy will be obtained.

Taking into account that the mRNA lipoparticle-based vaccinations against SARS-CoV-2 have achieved 95% efficacy [78], and that a Phase 1 tolerability study has been recently completed in healthy human adults, determining the dosing regime and pharmacodynamics of mRNA antibody expression against Chikungunya virus (6/2021, https://clinicaltrials.Gov/ct2/show/NCT03829384?term=mRNA-1944&rank=1, accessed on 2 August 2021), more adaptive pre-clinical to bedside trial designs towards the development of novel immune RNA medicines are urgently needed. Moreover, after the recent FDA emergency authorization, for clearing the use of monoclonal antibody administration also to immunosuppressed COVID-19 diagnosed patients presenting mild-to-moderate virus burden [79], the potential of the said therapies is upgraded. The development of additional monoclonal antibody modalities to meet the iterated demand is intrinsically linked to novel, reliable, pre-clinical development strategies, effectively implemented in the limited time-given work frame. Our study protocol contributes to this purpose by offering an elaborate method statement, one to guide the pre-clinical assessment of mRNA encoded monoclonal antibodies with special focus on their unmet application to immunosuppressed populations.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/vaccines9080890/s1, Table S1: SPIRIT checklist.
Author Contributions: Conceptualization, A.O. and N.K.; methodology, A.O.; software, A.O.; validation, A.O.; T.C.-P.; R.P. and N.K.; formal analysis, A.O.; investigation, A.O., N.K.; resources, A.O., T.C.-P.; data curation, A.O.; writing—original draft preparation, A.O., N.K., R.P., T.C.-P. and E.T.P.; writing—review and editing, A.O.; visualization, A.O. and E.T.P.; supervision, T.C.-P., N.K.; project administration, A.O.; funding acquisition, A.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research work, has been scheduled and realized for the implementation of the corresponding authors’ preparative action plan towards the “Spreading Excellence and Widening Participation Horizon Europe—Teaming 2021”. This research has been co-financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T1EDK-02775).

Institutional Review Board Statement: The study has been approved by the Institutional Project Evaluation Committee of BRFIA-Biomedical Research Foundation Academy of Athens (Ref. Num. 148/26-02-2021) and by the Directorate of Veterinary Department of Hellenic Republic (272243/07-04-2021/300627). The study protocol design strictly follows the (ARRIVE) ‘Animal Research: Reporting in-Vivo Experiments’ protocol guidelines’ as they have been updated for future human use.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. McHeyzer-Williams, M.G.; McHeyzer-Williams, L.J.; Fanelli Panus, J.; Bikah, G.; Pogue-Caley, R.R.; Driver, D.J.; Eisenbraun, M.D. Antigen-specific immunity: Th cell-dependent B cell responses. *Immunol. Res.* 2000, 22, 223–236. [CrossRef]

2. Merlo, L.M.F.; Mandik-Nayak, L. *Adaptive Immunity: B Cells and Antibodies*, 2nd ed.; Elsevier: Amsterdam, The Netherlands, 2013; ISBN 9780123942968.

3. DeKosky, B.J.; Kojima, T.; Rodin, A.; Charab, W.; Ippolito, G.C.; Ellington, A.D.; Georgiou, G. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. *Nat. Med.* 2015, 21, 86–91. [CrossRef]

4. Vidarsson, G.; Dekkers, G.; Rispens, T. IgG subclasses and allotypes: From structure to effector functions. *Front. Immunol.* 2014, 5, 1–17. [CrossRef]

5. Dekkers, G.; Bentlage, A.E.H.; Stegmann, T.C.; Howie, H.L.; Lissenberg-Thunnissen, S.; Zimring, J.; Rispens, T.; Vidarsson, G. Affinity of human IgG subclasses to mouse Fc gamma receptors. *Mabs* 2017, 9, 767–773. [CrossRef] [PubMed]

6. Joller, N.; Weber, S.S.; Oxenius, A. Antibody—Fc receptor interactions in protection against intracellular pathogens. *Eur. J. Immunol.* 2011, 41, 889–897. [CrossRef]

7. Sanseviero, E. NK Cell-Fc Receptors Advance Tumor Immunotherapy. *J. Clin. Med.* 2019, 8, 1667. [CrossRef] [PubMed]

8. Gao, Y.; Huang, X.; Zhu, Y.; Lv, Z. A brief review of monoclonal antibody technology and its representative applications in immunooassays. *J. Immunoass. Immunochem.* 2018, 39, 351–364. [CrossRef]

9. Yakes, F.M.; Chinratanalab, W.; Ritter, C.A.; King, W.; Seelig, S.; Arteaga, C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. *Cancer Res.* 2002, 62, 4132–4141.

10. Forssen, P.; Samuelsson, J.; Lacki, K.; Forstedt, T. Advanced analysis of biosensor data for SARS-CoV-2 RBD and ACE2 interactions. *Anal. Chem.* 2020, 92, 11520–11524. [CrossRef] [PubMed]

11. McKeage, K.; Perry, C.M. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. *Drugs* 2002, 62, 209–243. [CrossRef] [PubMed]

12. Staffans, I.; Annex I. In *Evidence in European Asylum Procedures*; Brill: Leiden, The Netherlands, 2012; p. 269.

13. Keizer, R.J.; Huitema, A.D.R.; Schellens, J.H.M.; Beijnen, J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. *Clin. Pharmacokinet.* 2010, 49, 493–507. [CrossRef]

14. Bruno, R.; Washington, C.B.; Lu, J.F.; Lieberman, G.; Banken, L.; Klein, P. Population pharmacokinetics of Trastuzumab in patients with HER2+ metastatic breast cancer. *Cancer Chemother. Pharmacol.* 2005, 56, 361–369. [CrossRef] [PubMed]

15. Samaranyake, H.; Wirth, T.; Schenkwein, D.; Räty, J.K.; Ylä-Herttuala, S. Challenges in monoclonal antibody-based therapies. *Ann. Med.* 2009, 41, 322–331. [CrossRef]

16. Awwad, S.; Angkawinitwong, U. Overview of antibody drug delivery. *Pharmaceutics* 2018, 10, 83. [CrossRef] [PubMed]

17. Rissanou, A.N.; Ouranidis, A.; Karatasos, K. Complexation of single stranded RNA with an ionizable lipid: An all-atom molecular dynamics simulation study. *Soft Matter* 2020, 16, 6993–7005. [CrossRef] [PubMed]

18. Karikó, K. In vitro-Transcribed mRNA Therapeutics: Out of the Shadows and Into the Spotlight. *Mol. Ther.* 2019, 27, 691–692. [CrossRef] [PubMed]

19. Schlake, T.; Thrän, M.; Fiedler, K.; Heidenreich, R.; Petsch, B.; Fotin-Mleczek, M. mRNA: A Novel Avenue to Antibody Therapy? *Mol. Ther.* 2019, 27, 773–784. [CrossRef] [PubMed]
20. Jackson, N.A.C.; Kester, K.E.; Casimiro, D.; Gurunathan, S.; DeRosa, F. The promise of mRNA vaccines: A biotech and industrial perspective. NPJ Vaccines 2020, 5, 3–8. [CrossRef] [PubMed]
21. Pitti, T.; Chen, C.T.; Lin, H.N.; Choong, W.K.; Hsu, W.L.; Sung, T.Y. N-GlyDE: A two-stage N-linked glycosylation site prediction incorporating gapped dipeptides and pattern-based encoding. Sci. Rep. 2019, 9, 1–11.
22. Liu, H.; Bulseco, G.G.; Sun, J. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol. Lett. 2006, 106, 144–153. [CrossRef]
23. de Taeye, S.W.; Bentlage, A.E.H.; Mebius, M.M.; Meesters, J.I.; Lissenberg-Thunnissen, S.; Falck, D.; Sénard, T.; Salehi, N.; Wuhrer, M.; Schuurman, J.; et al. FcyR Binding and ADCC Activity of Human IgG Alleotypes. Front. Immunol. 2020, 11, 1–16. [CrossRef] [PubMed]
24. Kanda, Y.; Yamada, T.; Mori, K.; Okazaki, A.; Inoue, M.; Kitajima-Miyama, K.; Kuni-Kamochi, R.; Nakano, R.; Yano, K.; Kakita, S.; et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 2007, 17, 104–118. [CrossRef] [PubMed]
25. Lindroth, K.; Mastache, E.F.; Roos, I.; Fernández, A.G.; Fernández, C. Understanding thymus-independent antigen-induced reduction of thymus-dependent immune responses. Immunology 2004, 112, 413–419. [CrossRef] [PubMed]
26. Calina, D.; Docea, A.O.; Petrakis, D.; Egorov, A.M.; Ishmukhametov, A.A.; Gabibov, A.G.; Stilman, M.I.; Kostoff, R.; Carvalho, F.; Vinceti, M.; et al. Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). Int. J. Mol. Med. 2020, 46, 3–16. [CrossRef] [PubMed]
27. Recino, A.; Gan, S.U.; Sia, K.C.; Sawyer, Y.; Trendell, J.; Kay, R.; Gribble, F.M.; Reimann, F.; Foale, R.; Notaridou, M.; et al. Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AA2V/8-mediated insulin gene therapy in NOD mice. Gene 2016, 526, 36–46. [CrossRef] [PubMed]
28. McKeen, D.; Hubpi, K.; Bell, M.; Staudt, L.; Gerhard, W.; Weigert, M. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 1984, 81, 3180–3184. [CrossRef]
29. Song, H.K.; Hwang, D.Y. Use of C57BL/6N mice on the variety of immunological researches. Lab. Anim. Res. 2017, 33, 119. [CrossRef]
30. Lock, R.B.; Liem, N.; Farnsworth, M.L.; Milross, C.G.; Xue, C.; Tajbakhsh, M.; Haber, M.; Norris, M.D.; Marshall, G.M.; Rice, A.M. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002, 99, 4100–4108. [CrossRef]
31. Scott, G.B.; De Wynter, E.A.; Cooke, G.P. Detecting variable (V), diversity (D) and joining (J) gene segment recombination using a two-colour fluorescence system. Mob. DNA 2010, 1, 1–6. [CrossRef] [PubMed]
32. Okada, S.; Vaeteeewoottacharn, K.; Kariya, R. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Cells 2019, 8, 889. [CrossRef]
33. Koyanagi, Y.; Tanaka, Y.; Kira, J.; Ito, M.; Hioki, K.; Misawa, N.; Kawano, Y.; Yamasaki, K.; Tanaka, R.; Suzuki, Y.; et al. Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain. J. Virol. 1997, 71, 2417–2424. [CrossRef] [PubMed]
34. Garrett, D.A. Proceedings of the SSIB 2016 Annual Meeting HHS Public Access. Physiol. Behav. 2011, 176, 139–148. [CrossRef] [PubMed]
35. Commission of European Communities. Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or im. Off. J. Eur. Union 2005, L, 13–19.
36. GCP, V.T.G. Guideline on Good Clinical Practices, Emea. 2000; pp. 1–29. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl9-good-clinical-practices-step-7_en.pdf (accessed on 17 August 2021).
37. EMEA. Statistical Principles for Veterinary Clinical Trials. Ann. Intern. Med. 2001, 81, 119–118. [CrossRef] [PubMed]
38. Osborne, N.; Avey, M.T.; Anestidou, L.; Ritskes-Hoitinga, M.; Griffin, G. Improving animal research reporting standards. EMBO Rep. 2018, 19, e46069. [CrossRef] [PubMed]
39. du Sert, N.P.; Hurst, V.; Abruwula, A.; Alam, S.; Avey, M.T.; Baker, M.; Browne, W.J.; Clark, A.; Cuthill, I.C.; Dinnagl, U.; et al. The arise guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020, 18, e3000410. [CrossRef]
40. National Research Council, N.R. Guide for the Care and Use of Laboratory Animals, 8th ed.; The National Academies Press: Washington, DC, USA, 2011; ISBN 978-0-309-15400-0.
41. Hro, A.; Mann, H.; Dickens, K.; Berlin, J.A.; Dore, C.J.; Parulekar, W.R.; Summerskill, W.S.M.; Groves, T.; Schulz, K.F.; Sox, H.C.; et al. Research and Reporting Methods Annals of Internal Medicine SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann. Intern. Med. 2015, 132, 200–207.
42. Bespalov, A.; Michel, M.C. Good Research Practice in Pharmacology and Biomedicine. 2020. Available online: http://link.springer.com/10.1007/978-3-030-33656-1 (accessed on 2 August 2021).
43. Di Paola, G.; Bertani, A.; De Monte, L.; Tuzzolino, F. A brief introduction to probability. J. Thorac. Dis. 2018, 10, 1129–1132. [CrossRef]
44. Kwak, S.G.; Kim, J.H. Cornerstone of Modern Statistics. Korean J. Anesthesiol. 2017, 70, 144–156. [CrossRef]
45. Wan, M.; Orlu-Gul, M.; Legay, H.; Tuleu, C. Blinding in pharmacological trials: The devil is in the details. Arch. Dis. Child. 2013, 98, 656–659. [CrossRef] [PubMed]
47. Viala, M.; Vinches, M.; Alexandre, M.; Mollevi, C.; Durigova, A.; Hayaoui, N.; Homiczko, K.; Cuenant, A.; Gongora, C.; Gianni, L.; et al. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: Tested doses and rationale for dose selection. Br. J. Cancer 2018, 118, 679–697. [CrossRef]

48. Ouranidis, A.; Gkampelis, N.; Vardaka, E.; Karagianni, A.; Tsipisios, D.; Nikolakakis, I.; Kachrimanis, K. Overcoming the solubility barrier of ibuprofen by the rational process design of a nanocrystal formulation. Pharmaceutics 2020, 12, 969. [CrossRef]

49. Ouranidis, A.; Gkampelis, N.; Markopoulou, C.; Nikolakakis, I.; Kachrimanis, K. Development of a Nanocrystal Formulation of a Low Melting Point API Following a Quality by Design Approach. Processes 2021, 9, 954. [CrossRef]

50. Brophy, J.A.N.; Voigt, C.A. Principles of genetic circuit design. Nat. Methods 2014, 11, 508–520. [CrossRef]

51. Karlin, S.; Altschul, S.F. Applications and statistics for multiple high-scoring segments in molecular sequences. Proc. Natl. Acad. Sci. USA 1993, 90, 5873–5877. [CrossRef]

52. Kudla, G.; Lipinski, L.; Caffin, F.; Helvak, A.; Zylicz, M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 2006, 4, 933–942. [CrossRef]

53. Akashi, H. Gene expression and molecular evolution. Curr. Opin. Genet. Dev. 2001, 11, 660–666. [CrossRef]

54. Caput, D.; Beutler, B.; Hartog, K.; Thayer, R.; Brown-Shimer, S.; Cerami, A. Identification of a common nucleotide sequence motif in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA 1996, 83, 1670–1674. [CrossRef]

55. Jani, B.; Fuchs, R. In vitro transcription and capping of Gaussia luciferase mRNA followed by HeLa cell transfection. J. Vis. Exp. 2012, 61, 3702. [CrossRef]

56. Grudzien, E.; Stepinski, J.; Jankowska-Anyzuka, M.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R.E. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 2004, 10, 1479–1487. [CrossRef] [PubMed]

57. Zhang, X.; Zhao, W.; Nguyen, G.N.; Zhang, C.; Zeng, C.; Yan, J.; Du, S.; Hou, X.; Li, W.; Jiang, J.; et al. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci. Adv. 2020, 6, 1–9. [CrossRef] [PubMed]

58. Kauffman, K.J.; Dorkin, J.R.; Yang, J.H.; Heartlein, M.W.; Derosa, F.; Mir, F.F.; Fenton, O.S.; Anderson, D.G. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional factorial and Definitive Screening Designs. Nano Lett. 2015, 15, 7300–7306. [CrossRef] [PubMed]

59. Roces, C.B.; Lou, G.; Jain, N.; Abraham, S.; Thomas, A.; Halbert, G.W.; Perrie, Y. Manufacturing considerations for the development of lipid nanoparticles using microfluidics. Pharmaceutics 2020, 12, 1095. [CrossRef]

60. European Medicines Agency. Guidance for the Template for the Qualified Person’s Declaration Concerning GMP Compliance of Active Substance Manufacture “The QP Declaration Template.” 2014, Volume 44. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy_en.pdf (accessed on 2 August 2021).

61. European Medicines Agency. ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities). Eur. Med. Agency 2012, 224, 69634–69635.

62. European Medicines Agency. Guidance for the Template for the Qualified Person’s Declaration Concerning GMP Compliance of Active Substance Manufacture “The QP Declaration Template.” 2014, Volume 44. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy_en.pdf (accessed on 2 August 2021).

63. Knoblaugh, S.E.; Hohl, T.M.; La Perle, K.M.D. Pathology Principles and Practices for Analysis of Animal Models. ILAR J. 2018, 59, 40–50. [CrossRef]

64. Denayer, T.; Stöhr, T.; Van Roy, M. Animal models in translational medicine: Validation and prediction. New Horiz. Transl. Med. 2014, 2, 5–11. [CrossRef]

65. Danial, J.S.; Aguibi, Y.; Yacoub, M.H. Advanced fluorescence microscopy techniques for the life sciences. Glob. Cardiol. Sci. Pract. 2016, 2016, e201616. [CrossRef]

66. Woodworth, A.; Thompson, M.A.; Rice, T.; Bissonnette, S. Biochemical and hematological markers of inflammation accurately predict sepsis and its severity in ICU patients. Sysmex J. Int. 2019, 29, 1–7.

67. Mackensen, D.G.; Jain, R.K. Physiologically Based Pharmacokinetic Model for Specific and Nonspecific Monoclonal Antibodies and Fragments in Normal Tissues and Human Tumor Xenografts in Nude Mice1. Cancer Res. 1994, 54, 1517–1528.

68. Shah, D.K.; Betts, A.M. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J. Pharmacobiotic. Pharmacodyn. 2012, 39, 67–86. [CrossRef]

69. Forssén, P.; Multia, E.; Samuelsson, J.; Andersson, M.; Aastrup, T.; Amtun, S.; Wallinder, D.; Wallbing, L.; Liangsupree, T.; Riekola, M.L.; et al. Reliable Strategy for Analysis of Complex Biosensor Data. Anal. Chem. 2018, 90, 5366–5374. [CrossRef]

70. Li, L.; Gardner, I.; Dostalek, M.; Jamei, M. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J. 2014, 16, 1097–1109. [CrossRef]

71. Bulitta, J.B.; Holford, N.H.G. Noncompartmental Analysis. Methods Appl. Stat. Clin. Trials 2014, 2, 457–482.

72. Hirst, J.A.; Howick, J.; Aronson, J.K.; Roberts, N.; Perera, R.; Koshiaris, C.; Heneghan, C. The need for randomization in animal trials: An overview of systematic reviews. PLoS ONE 2014, 9, e98856. [CrossRef]

73. Cummings, J.; Tractenberg, R.; Gamst, A.; Teri, L.; Masterman, D.; Thal, L. Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia. Curr. Alzheimer Res. 2005, 1, 323–328. [CrossRef] [PubMed]
74. Benedetti, F. Mechanisms of placebo and placebo-related effects across diseases and treatments. *Annu. Rev. Pharmacol. Toxicol.* 2008, 48, 33–60. [CrossRef] [PubMed]

75. Lipton, R.B.; Micieli, G.; Russell, D.; Solomon, S.; Tfelt-Hansen, P.; Waldenlind, E. Guidelines for controlled trials of drugs in cluster headache. *Cephalalgia* 1995, 15, 452–4526. [CrossRef]

76. The European Medicines Agency’s (EMEA’s). Overview of Comments ‘Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies’. Available online: https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-similar-biological-medicinal-products-containing-monoclonal/chmp/bmwp/403543/2010_en.pdf (accessed on 10 August 2021).

77. McCoy, C.E. Understanding the intention-to-treat principle in randomized controlled trials. *West. J. Emerg. Med.* 2017, 18, 1075–1078. [CrossRef] [PubMed]

78. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J. Med.* 2021, 384, 403–416. [CrossRef]

79. Taylor, P.C.; Adams, A.C.; Hufford, M.M.; de la Torre, I.; Winthrop, K.; Gottlieb, R.L. Neutralizing monoclonal antibodies for treatment of COVID-19. *Nat. Rev. Immunol.* 2021, 21, 382–393. [CrossRef] [PubMed]